Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Tools Stocks Rise on Roche Bid for Illumina

NEW YORK (GenomeWeb News) – The stocks of many players in the genomics tools field rose yesterday following Roche's $5.7 billion hostile takeover bid for Illumina.

Analysts who cover the industry said yesterday that they expected the shares of other sequencing players to rise, and for the most part they did. Life Technologies climbed 4 percent to close at $49.09, Complete Genomics jumped 20 percent to $2.99, and Pacific Biosciences increased 16 percent to $4.59.

Shares of Illumina closed up 46 percent at $55.15, well above the $44.50 per share offered by Roche. But many industry observers believe Roche will have to significantly increase its offer to have a chance of getting a deal done.

"Given that the stock was trading in the $70s a few months ago and our DCF analysis indicates that the intrinsic value of Illumina shares could be as a high as $71, we believe the Roche bid will need to increase to gain shareholder support," William Blair analyst Amanda Blair said in a research note yesterday.

Some analysts also have suggested other big life science players, such as GE or Siemens, could also be interested.

Among other players in the genomics tools space, Qiagen closed up 7 percent at $16.76 and Fluidigm rose 7 percent to close at $14.86.

Several molecular diagnostics firms also saw a bump on Wednesday with Cepheid rising 5 percent, Gen-Probe up 5 percent, and Nanosphere closing up 7 percent.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.